Pluristem Therapeutics Inc. is a biotechnology company that is developing off-the-shelf cell therapies for a variety of human diseases. The company's cell products are derived from human placentas, traditionally left to be medical waste following childbirth. Pluristem expands these placental-derived cells with the use of a unique, proprietary, three-dimensional technology platform that ensures the efficient, controlled mass production of its cell therapy products, termed PLacental eXpanded cells.